Keyword: Otsuka Pharmaceutical
AZ expects COVID-19 to slow its growth. Health regulators warn of potential drug shortages. Akebia will use a priority review voucher on vadadustat.
Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.
Avanir is laying off 140 employees, a WARN notice in California shows, shortly after its $116 million Nuedexta marketing settlement with the feds.
Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.
Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.
Avanir has reached a settlement with the feds over a yearslong marketing and kickbacks probe for Nuedexta.
Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.
AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.
More than a year after CNN's exposé about Avanir's Neudexta marketing, the company is nearing a settlement with U.S. officials.
Antengene collects $120 million in series B; Otsuka inks new digital-pill pact; MabSpace merges with HJB.